Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIRB 1017 BS in healthy male subjects
NCT02184338Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2004
- Primary completion
- Nov 2004
01
Overview
Phase 1, randomised, double-blind trial in rheumatoid arthritis (RA) comparing BIRB 1017 BS with Placebo (2 arms). Primary endpoints: Assessment of safety and tolerability by the investigator on a 4-point scale, Number of patients with adverse events at 25 days and 3 more. Started Aug 2004; status: completed.
02
Drugs
BIRB-1017
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02184338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02184338.